Key Molecular Pathway Driving Spinal Cord Scarring Identified

A groundbreaking study published in Burns & Trauma reveals a key molecular mechanism driving fibrotic scarring after spinal cord injury (SCI). Researchers from multiple Chinese institutions identified the c-Jun–Irf8–CD36 axis as a critical pathway that promotes excessive fibrosis, which forms a dense barrier blocking axon regrowth and limiting functional recovery. Using advanced techniques like single-cell RNA sequencing and spatial transcriptomics, they pinpointed CD36-enriched fibroblast subpopulations that accumulate in lesion scars. The study demonstrates that targeting CD36 with salvianolic acid B (SAB) or its upstream regulator c-Jun with T5224 can reduce fibrotic scar formation, improve vascular remodeling, support axonal regeneration, and enhance motor recovery in mouse models. These findings offer a more precise approach to managing spinal cord scars—rather than removing scar tissue entirely, the goal is to modulate it at the right stage to preserve its early protective role while preventing long-term fibrosis.

Spinal cord injury often results in permanent motor and sensory deficits because the damaged tissue fails to regenerate effectively. After injury, a complex lesion microenvironment forms involving astrocytes, fibroblasts, immune cells, blood vessels, and extracellular matrix components. While acute scar formation helps limit inflammation and stabilize the injury, persistent fibroblast activation leads to excessive ECM deposition that blocks regeneration. Current treatments like decompression surgery and anti-inflammatory drugs focus on reducing secondary damage rather than reshaping the scar itself. This study, published with DOI 10.1093/burnst/tkag020, provides a molecular roadmap for developing stage-adapted therapies that target pathogenic fibroblasts while preserving tissue stability. The research team showed that the c-Jun–Irf8–CD36 signaling cascade drives CD36 expression in specific fibroblast subclusters, and inhibiting this axis shifts fibroblasts toward a less fibrotic, more repair-permissive phenotype.

The implications are significant for SCI treatment. Both CD36 and c-Jun are pharmacologically targetable, opening avenues for localized drug delivery, combination therapy, or precision approaches that act on harmful fibroblast subtypes. The study also highlights how single-cell RNA sequencing and spatial transcriptomics can reveal not only which cells are present at an injury site but also where they act and how they change after treatment. Further validation in larger animal models and preclinical systems is needed before translation to human therapy, but this work lays a strong foundation for scar biology-based interventions that could improve functional outcomes for SCI patients.